军事知识服务平台
急性白血病治疗所致血小板减少症诊疗中国专家共识(2026年版)
Chinese expert consensus on the diagnosis and treatment of acute leukemia treatment-induced thrombocytopenia (2026 version)
摘要 急性白血病患者因接受化疗、靶向药物、免疫治疗等导致的血小板减少症是临床常见的并发症,其增加了患者的出血风险,并影响治疗效果,也是患者治疗后常见的致死原因。目前急性白血病治疗所致血小板减少症的防治措施主要包括血小板输注、重组人白细胞介素11、重组人血小板生成素、血小板生成素受体激动剂等的应用。共识专家组参考国内外相关临床研究和循证医学证据,提出了针对该并发症的治疗和预防方法,旨在促进临床规范合理用药,供中国血液科临床医生参考。
Abstract:
Thrombocytopenia caused by chemotherapy, targeted therapy and immunotherapy is a common clinical complication in patients with acute leukemia. It raises the risk of bleeding, compromises treatment efficacy, and often contributes to post-treatment mortality. Current preventive and therapeutic measures for acute leukemia treatment-induced thrombocytopenia mainly relies on platelet transfusion, recombinant human interleukin-11, recombinant human thrombopoietin, and thrombopoietin receptor agonists, etc. Relevant domestic and international clinical studies and evidence-based medical evidence were reviewed by the consensus panel, and therapeutic and prophylactic approaches for this complication were proposed to promote standardized and rational medication use, and serve as a reference for hematologists in China.